Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Cholesteryl hemisuccinate (CHEMS) is an acidic cholesterol ester with anticancer activity. It is an oxidation product of polyunsaturated fatty acid of cholesterol that can alter lysosome structure and functions, as well as induce proinflammatory cytokine production in macrophages. Cholesteryl hemisuccinate acts as an ionizable anionic detergent and is commonly used to stabilize unilamellar vesicles and liposomes.

1510-21-0

Post Buying Request

1510-21-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1510-21-0 Usage

Uses

Used in Anticancer Applications:
Cholesteryl hemisuccinate is used as an anticancer agent for inhibiting the growth of murine C1498 myeloid and L1210 lymphocytic leukemia cells when used at concentrations of 50 and 150 μM, respectively.
Used in Drug Delivery Systems:
Cholesteryl hemisuccinate is used as a stabilizing agent for unilamellar vesicles and liposomes, which are essential components in various vesicular drug delivery systems. These systems are designed to improve the delivery, bioavailability, and therapeutic outcomes of anticancer drugs, antibiotics, and oligonucleotides.
Used in Emulsification:
Cholesteryl hemisuccinate is used as an emulsifying agent in the pharmaceutical industry to solubilize various proteins, including chemokine receptor 1 and erythrocyte ghosts, enhancing the stability and effectiveness of these proteins in various applications.

Biochem/physiol Actions

CHEMS can help to maintain the stability of dioleoylphosphatidylethanolamine (DOPE). This amphipathic lipid is used in mixtures with dioleoylphosphatidylethanolamine (DOPE) to form ′pH sensitive′ fusogenic vesicles. It can control cell growth.

Check Digit Verification of cas no

The CAS Registry Mumber 1510-21-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,5,1 and 0 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1510-21:
(6*1)+(5*5)+(4*1)+(3*0)+(2*2)+(1*1)=40
40 % 10 = 0
So 1510-21-0 is a valid CAS Registry Number.
InChI:InChI=1/C31H50O4/c1-20(2)7-6-8-21(3)25-11-12-26-24-10-9-22-19-23(35-29(34)14-13-28(32)33)15-17-30(22,4)27(24)16-18-31(25,26)5/h9,20-21,23-27H,6-8,10-19H2,1-5H3,(H,32,33)

1510-21-0 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma

  • (C6512)  Cholesterylhemisuccinate  

  • 1510-21-0

  • C6512-5G

  • 2,306.07CNY

  • Detail
  • Sigma

  • (C6512)  Cholesterylhemisuccinate  

  • 1510-21-0

  • C6512-25G

  • 7,973.55CNY

  • Detail

1510-21-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017

1.Identification

1.1 GHS Product identifier

Product name Cholesteryl hemisuccinate

1.2 Other means of identification

Product number -
Other names CHOLESTEROL HYDROGEN SUCCINATE

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1510-21-0 SDS

1510-21-0Synthetic route

succinic acid anhydride
108-30-5

succinic acid anhydride

cholesterol
57-88-5

cholesterol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
With pyridine; dmap; dimethyl sulfoxide In chloroform at 110℃; for 3h;97%
With pyridine; dmap at 20℃; for 168h;96%
Stage #1: succinic acid anhydride; cholesterol; dmap In 1,4-dioxane at 20℃; for 24h;
Stage #2: With hydrogenchloride In 1,4-dioxane; water
95%
5-cholesten-3β-yl 2-(trimethylsilyl)ethyl butanedioate
92803-49-1

5-cholesten-3β-yl 2-(trimethylsilyl)ethyl butanedioate

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
With tetrabutyl ammonium fluoride In tetrahydrofuran at 27℃; for 2h;95%
With tetrabutyl ammonium fluoride In tetrahydrofuran at 20℃;81%
cholesterol
57-88-5

cholesterol

succinoyl dichloride
543-20-4

succinoyl dichloride

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
Stage #1: cholesterol; succinoyl dichloride In acetonitrile at 50℃; for 12h;
Stage #2: With hydrogenchloride In water; acetonitrile
92%
succinic acid anhydride
108-30-5

succinic acid anhydride

cholesterol
57-88-5

cholesterol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
With toluene-4-sulfonic acid; benzene
With pyridine; toluene-4-sulfonic acid
cholesterol
57-88-5

cholesterol

succinoyl dichloride
543-20-4

succinoyl dichloride

A

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

B

cholesteryl 3-succinate
1510-20-9

cholesteryl 3-succinate

Conditions
ConditionsYield
With benzene
cholesterol
57-88-5

cholesterol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 85 percent / DCC, 4-dimethylaminopyridine / benzene / 5 h / 27 °C
2: 95 percent / tetrabutylammonium fluoride / tetrahydrofuran / 2 h / 27 °C
View Scheme
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

cholesteryloxycarbonylpropionyl chloride
87311-35-1

cholesteryloxycarbonylpropionyl chloride

Conditions
ConditionsYield
With thionyl chloride In toluene at 90℃; for 2h;100%
With oxalyl dichloride In dichloromethane at 20℃; for 12h;98%
With thionyl chloride In toluene at 80℃; for 1h;
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

2-mercaptothiazoline
96-53-7

2-mercaptothiazoline

C34H53NO3S2

C34H53NO3S2

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 1h;100%
(2-aminomethylpyridine)
3731-51-9

(2-aminomethylpyridine)

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

(3β)-cholest-5-en-3-yl 4-oxo-4-[(pyridin-2-ylmethyl)amino]butanoate

(3β)-cholest-5-en-3-yl 4-oxo-4-[(pyridin-2-ylmethyl)amino]butanoate

Conditions
ConditionsYield
With pyridine; 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide In ethyl acetate at 20℃; for 75h; Reagent/catalyst; Solvent;96%
succinic acid anhydride
108-30-5

succinic acid anhydride

cholesterol
57-88-5

cholesterol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
With pyridine; dmap; dimethyl sulfoxide In chloroform at 110℃; for 3h;97%
With pyridine; dmap at 20℃; for 168h;96%
Stage #1: succinic acid anhydride; cholesterol; dmap In 1,4-dioxane at 20℃; for 24h;
Stage #2: With hydrogenchloride In 1,4-dioxane; water
95%
5-cholesten-3β-yl 2-(trimethylsilyl)ethyl butanedioate
92803-49-1

5-cholesten-3β-yl 2-(trimethylsilyl)ethyl butanedioate

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
With tetrabutyl ammonium fluoride In tetrahydrofuran at 27℃; for 2h;95%
With tetrabutyl ammonium fluoride In tetrahydrofuran at 20℃;81%
cholesterol
57-88-5

cholesterol

succinoyl dichloride
543-20-4

succinoyl dichloride

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
Stage #1: cholesterol; succinoyl dichloride In acetonitrile at 50℃; for 12h;
Stage #2: With hydrogenchloride In water; acetonitrile
92%
succinic acid anhydride
108-30-5

succinic acid anhydride

cholesterol
57-88-5

cholesterol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
With toluene-4-sulfonic acid; benzene
With pyridine; toluene-4-sulfonic acid
cholesterol
57-88-5

cholesterol

succinoyl dichloride
543-20-4

succinoyl dichloride

A

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

B

cholesteryl 3-succinate
1510-20-9

cholesteryl 3-succinate

Conditions
ConditionsYield
With benzene
cholesterol
57-88-5

cholesterol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 85 percent / DCC, 4-dimethylaminopyridine / benzene / 5 h / 27 °C
2: 95 percent / tetrabutylammonium fluoride / tetrahydrofuran / 2 h / 27 °C
View Scheme
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

cholesteryloxycarbonylpropionyl chloride
87311-35-1

cholesteryloxycarbonylpropionyl chloride

Conditions
ConditionsYield
With thionyl chloride In toluene at 90℃; for 2h;100%
With oxalyl dichloride In dichloromethane at 20℃; for 12h;98%
With thionyl chloride In toluene at 80℃; for 1h;
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

2-mercaptothiazoline
96-53-7

2-mercaptothiazoline

C34H53NO3S2

C34H53NO3S2

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 1h;100%
(2-aminomethylpyridine)
3731-51-9

(2-aminomethylpyridine)

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

(3β)-cholest-5-en-3-yl 4-oxo-4-[(pyridin-2-ylmethyl)amino]butanoate

(3β)-cholest-5-en-3-yl 4-oxo-4-[(pyridin-2-ylmethyl)amino]butanoate

Conditions
ConditionsYield
With pyridine; 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide In ethyl acetate at 20℃; for 75h; Reagent/catalyst; Solvent;96%
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

1-stearoyl-sn-glycero-3-phosphocholine
17364-19-1

1-stearoyl-sn-glycero-3-phosphocholine

1-stearoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine

1-stearoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In chloroform at 20℃; for 24h;90%
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

5α,6β-dihydroxycholestan-3β-yl-hemisuccinate
10157-97-8

5α,6β-dihydroxycholestan-3β-yl-hemisuccinate

Conditions
ConditionsYield
Stage #1: cholesteryl hemisuccinate With monoperoxyphthalic acid magnesium salt hexahydrate In acetone at 57℃; for 0.5h;
Stage #2: With bismuth(lll) trifluoromethanesulfonate In acetone at 20℃; for 0.5h;
90%
1-hydroxy-pyrrolidine-2,5-dione
6066-82-6

1-hydroxy-pyrrolidine-2,5-dione

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

cholesterol-NHS ester
88848-79-7

cholesterol-NHS ester

Conditions
ConditionsYield
With dicyclohexyl-carbodiimide In tetrahydrofuran at -10 - 20℃; for 4h;89%
With dicyclohexyl-carbodiimide In dichloromethane; N,N-dimethyl-formamide
With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 1.5h;
C17H20ClNO4S

C17H20ClNO4S

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Ethyl-diisopropylphosphoramidochloridit
104495-49-0

Ethyl-diisopropylphosphoramidochloridit

ethylene glycol
107-21-1

ethylene glycol

C52H77ClNO11PS

C52H77ClNO11PS

Conditions
ConditionsYield
at 20℃; for 10h;85.7%
monomethoxypolyethylene glycol-polylactide

monomethoxypolyethylene glycol-polylactide

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

mPEG-PLA-cholesterol

mPEG-PLA-cholesterol

Conditions
ConditionsYield
dmap; dicyclohexyl-carbodiimide In acetonitrile at 20℃; for 24h; Product distribution / selectivity;85%
8-dioxane-3-cobalt-bis(1,2-dicarbollide)
188478-29-7

8-dioxane-3-cobalt-bis(1,2-dicarbollide)

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

potassium carbonate
584-08-7

potassium carbonate

C39H78B18CoO6(1-)*K(1+)

C39H78B18CoO6(1-)*K(1+)

Conditions
ConditionsYield
In 1,2-dimethoxyethane for 6h; Reflux;83%
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

1,1'-carbonyldiimidazole
530-62-1

1,1'-carbonyldiimidazole

C34H52N2O3

C34H52N2O3

Conditions
ConditionsYield
In chloroform at 38℃; for 8h;81%
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

3,6,9,12,15,18-hexaoxa-1-octadecyl amine
39160-70-8

3,6,9,12,15,18-hexaoxa-1-octadecyl amine

N-{2-[2-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethyl}-succinamic acid 17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester
878049-46-8

N-{2-[2-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethyl}-succinamic acid 17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester

Conditions
ConditionsYield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 0 - 20℃; for 20h;80%
3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-propanol
926890-48-4

3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-propanol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

A

3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-[succinyloxy(4-cholesteryloxy)]propane
926890-49-5

3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-[succinyloxy(4-cholesteryloxy)]propane

B

1,3-Dicyclohexylurea
2387-23-7

1,3-Dicyclohexylurea

Conditions
ConditionsYield
With dicyclohexyl-carbodiimide In N,N-dimethyl-formamide at 0 - 20℃; for 6.08333h; Product distribution / selectivity;A 79%
B n/a
3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-propanol
926890-48-4

3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-propanol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-[succinyloxy(4-cholesteryloxy)]propane
926890-49-5

3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-[succinyloxy(4-cholesteryloxy)]propane

Conditions
ConditionsYield
With dicyclohexyl-carbodiimide In dichloromethane at 0 - 20℃; for 6h; Product distribution / selectivity;79%
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

5'-O-dimethoxytrityl-2'-amino-2'-deoxyuridine
174221-86-4

5'-O-dimethoxytrityl-2'-amino-2'-deoxyuridine

C61H79N3O10

C61H79N3O10

Conditions
ConditionsYield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 24h;79%
3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-propanol

3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-propanol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-[succinyloxy(4-cholesteryloxy)]propane
926890-49-5

3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-[succinyloxy(4-cholesteryloxy)]propane

Conditions
ConditionsYield
With dicyclohexyl-carbodiimide In N,N-dimethyl-formamide at 20℃; for 6h; Cooling with ice;79%
(Bu4N)3{(MnMo6O18)3[(OCH2)3CNH2]2}

(Bu4N)3{(MnMo6O18)3[(OCH2)3CNH2]2}

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

C8H16MnMo6N2O24(3-)*C16H36N(1+)*C31H50O4

C8H16MnMo6N2O24(3-)*C16H36N(1+)*C31H50O4

Conditions
ConditionsYield
Stage #1: cholesteryl hemisuccinate With N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline In acetonitrile at 81℃; for 0.583333h;
Stage #2: (Bu4N)3{(MnMo6O18)3[(OCH2)3CNH2]2} In acetonitrile for 24h; Reflux;
79%
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

6A,6D-diamino-6A,6D-dideoxy-2A,D,3A,D-di-O-methylhexakis-(2A-G,3B-G,6B,C,E,F,G-tri-O-methyl)cyclomaltoheptaose
405906-58-3

6A,6D-diamino-6A,6D-dideoxy-2A,D,3A,D-di-O-methylhexakis-(2A-G,3B-G,6B,C,E,F,G-tri-O-methyl)cyclomaltoheptaose

6(I),6(IV)-(β-cholesteryl)-succinylamido-6(I),6(IV)-6-deoxy-per(2,3,6-O-methyl)cycloheptaose

6(I),6(IV)-(β-cholesteryl)-succinylamido-6(I),6(IV)-6-deoxy-per(2,3,6-O-methyl)cycloheptaose

Conditions
ConditionsYield
With benzotriazol-1-ol; dicyclohexyl-carbodiimide In N,N-dimethyl-formamide at 20℃; for 3h;78%
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

7-ethyl-10-hydroxycamptothecin
86639-52-3, 110714-48-2, 130144-34-2

7-ethyl-10-hydroxycamptothecin

cholesterol succinate-10-(7-ethyl-10-hydroxycamptothecin)

cholesterol succinate-10-(7-ethyl-10-hydroxycamptothecin)

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 18h;78%
With pyridine; dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 25℃;71.8%
With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; 4-(dimethylamino)pyridinium tosylate In dichloromethane at 20℃; for 2.5h;70%
N-hydroxyphthalimide
524-38-9

N-hydroxyphthalimide

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl (1,3-dioxoisoindolin-2-yl) succinate

(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl (1,3-dioxoisoindolin-2-yl) succinate

Conditions
ConditionsYield
With dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 16h; Inert atmosphere;75%
2-methyl-2-propenoic acid 2-hydroxyethyl ester
868-77-9

2-methyl-2-propenoic acid 2-hydroxyethyl ester

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

2-(3-((cholesteryl)oxycarbonyl)propionyloxy)ethyl methacrylate
107674-10-2

2-(3-((cholesteryl)oxycarbonyl)propionyloxy)ethyl methacrylate

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; Cooling with ice;74%
5-fluorouracil
51-21-8

5-fluorouracil

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

cholesteryl 4-(2,4-dioxo-5-fluoro-(1H,3H)-pyrimidin-1-yl)-4-oxobutanoate

cholesteryl 4-(2,4-dioxo-5-fluoro-(1H,3H)-pyrimidin-1-yl)-4-oxobutanoate

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In tetrahydrofuran; N,N-dimethyl-formamide at 50℃; for 48h;72%
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

3-(cholesteryloxycarbonyl)propanoyl MMC
118022-81-4

3-(cholesteryloxycarbonyl)propanoyl MMC

Conditions
ConditionsYield
With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In tetrahydrofuran; chloroform for 48h; Ambient temperature;71%
2-( N-ethylanilino)ethanol
92-50-2

2-( N-ethylanilino)ethanol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

2-(N-ethyl-N-phenylamino)ethyl 3'-((cholesteryl)oxycarbonyl)propionate

2-(N-ethyl-N-phenylamino)ethyl 3'-((cholesteryl)oxycarbonyl)propionate

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 24h;70%
radicicol

radicicol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

C49H65ClO9

C49H65ClO9

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 48h;70%
4-{[(2-hydroxyethyl)(2-naphthylmethyl)amino]methyl}-N-(tetrahydro-2H-pyran-2-yloxy)benzamide
1198587-13-1

4-{[(2-hydroxyethyl)(2-naphthylmethyl)amino]methyl}-N-(tetrahydro-2H-pyran-2-yloxy)benzamide

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

1-cholest-5-en-3-yl 4-{2-[(2-naphthylmethyl)(4-{[(tetrahydro-2H-pyran-2-yloxy)amino]carbonyl}benzyl)amino]ethyl} succinate
1198587-15-3

1-cholest-5-en-3-yl 4-{2-[(2-naphthylmethyl)(4-{[(tetrahydro-2H-pyran-2-yloxy)amino]carbonyl}benzyl)amino]ethyl} succinate

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 4h;65.8%
4,6-diphenylthieno-[3,4-d]-1,3-dioxol-2-one-5,5-dioxide
54714-11-3

4,6-diphenylthieno-[3,4-d]-1,3-dioxol-2-one-5,5-dioxide

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Succinic acid (3S,8S,9S,10R,13R,14S,17R)-17-((R)-1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester 1,1,4-trioxo-2,5-diphenyl-4,5-dihydro-1H-1λ6-thiophen-3-yl ester
127619-26-5

Succinic acid (3S,8S,9S,10R,13R,14S,17R)-17-((R)-1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester 1,1,4-trioxo-2,5-diphenyl-4,5-dihydro-1H-1λ6-thiophen-3-yl ester

Conditions
ConditionsYield
With pyridine In dichloromethane at 20℃; for 24h;64%
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

ethylene glycol
107-21-1

ethylene glycol

Succinic acid (3S,8S,9S,10R,13R,14S,17R)-17-((R)-1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester 2-hydroxy-ethyl ester
204652-39-1

Succinic acid (3S,8S,9S,10R,13R,14S,17R)-17-((R)-1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester 2-hydroxy-ethyl ester

Conditions
ConditionsYield
Stage #1: cholesteryl hemisuccinate With thionyl chloride In toluene at 65℃;
Stage #2: ethylene glycol With triethylamine In dichloromethane at 20℃;
63%
Stage #1: cholesteryl hemisuccinate With thionyl chloride In toluene
Stage #2: ethylene glycol With triethylamine In dichloromethane at 20℃;

1510-21-0Relevant articles and documents

Cholesterol-linked β-cyclodextrin - A thermotropic liquid-crystalline derivative

Shaikh, Vasi Ahmed Ebrahim,Lonikar, Shrikant Vitthal,Dhobale, Deepa Arun,Pawar

, p. 1975 - 1980 (2007)

Liquid-crystalline derivative of β-cyclodextrin (BCD) was prepared by covalent linking of monocholesteryl succinate (ChMS) with β-cyclodextrin. To the best of our knowledge, this was first ever attempt so far of its kind, in which BCD has been converted into its liquid-crystalline derivative through covalent linkage of a mesogen. The degree of substitution (DS) obtained was ≈2.00. The product was characterized by various techniques, such as FT-IR, NMR, DSC, hot-stage-coupled optical polarizing microscopy (OPM), microanalysis and chemical methods. Cholesterol-linked β-cyclodextrin (CDCh) derivative was found to exhibit thermotropic liquid-crystalline behavior. The product exhibited birefringence during first heating above 130°C, and it became isotropic at about 180°C, whereas the parent compound BCD decomposed without melting above 250 °C. A comparison of CDCh derivative to similar liquid-crystalline poly-saccharide derivatives is presented.

A novel truncated basic fibroblast growth factor fragment-conjugated poly (ethylene glycol)-cholesterol amphiphilic polymeric drug delivery system for targeting to the FGFR-overexpressing tumor cells

Cai, Lulu,Qiu, Neng,Li, Xia,Luo, Kaili,Chen, Xiang,Yang, Li,He, Gu,Wei, Yuquan,Chen, Lijuan

, p. 173 - 182 (2011)

Targeted uptake of therapeutic nanoparticles in tumor cells-specific manner represents a potentially powerful technology in cancer therapy. In present study, we proposed a drug delivery system formulated with biocompatible and biodegradable cholesterol-block-poly (ethylene glycol) (Chol-PEG 2000-COOH) polymer. And the surface of the polymer was chemically linked with truncated bFGF fragments (tbFGF). The tbFGF could recognize fibroblast growth factor receptors (FGFR) that are highly expressed by a variety of human cancer cells. The micelles had a size distribution of about 10-50 nm and significantly enhanced the cytotoxicity of paclitaxel to LL/2 cells as demonstrated by MTT test (IC50 = 0.21 μg/mL for tbFGF conjugated Chol-PEG2000-COOH micelles (tbFGF-M-PTX) versus 26.43 μg/mL for free paclitaxel, respectively). Flow cytometry revealed the cellular uptake of rhodamine B encapsulated in the tbFGF-conjugated micelles was increased by 6.6-fold for HepG2, 6.2-fold for A549, 2.9-fold for C26 and 2.7-fold for LL/2 tumor cells, respectively, compared with micelles without tbFGF. The fluorescence spectroscopy images further demonstrated that the tbFGF conjugated micelles could specifically bind to the tumor cells that over-expressed FGFRs and then release rhodamine B into the cytoplasm. Our results suggest the tbFGF conjugated Chol-PEG2000-COOH micelles have great potential application for tumor targeting therapy.

Poly(N-propargylamide)s bearing cholesteryl moieties: Preparation and optical activity

Zhang, Chaohong,Liu, Dong,Zhou, Bolin,Deng, Jianping,Yang, Wantai

, p. 832 - 838 (2012)

We synthesized a novel chiral cholesteryl-based N-propargylamide (M ch, HCCCH2NHCOCH2CH2COOch, ch = cholesteryl) from which homopolymers [P(Mch)] with different molecular weights (number-average molecular weight: 8600, 14100 and 30000) were prepared. The polymers formed helical structures with a preferential helicity. The three polymers increased in both helix content and specific rotation as the molecular weight increased. P(Mch)-8600 was studied in detail as the model polymer. P(Mch)-8600 adopted helical conformations in toluene, THF, CHCl3 and CH2Cl2, exhibited thermal stability with a decomposition temperature of 273°C and formed a lyotropic liquid crystal under the studied conditions. Copolymers of different compositions of Mch and an achiral monomer (Met) were prepared. The copolymers formed helices to different degrees depending on the specific composition, indicating an effective approach for controlling the formation of helices in synthetic helical polymers.

Design and synthesis of new cholesterol-conjugated 5-fluorouracil: A novel potential delivery system for cancer treatment

Radwan, Awwad A.,Alanazi, Fares K.

, p. 13177 - 13187 (2014)

Cholesterol-conjugated 5-fluorouracil prodrugs were designed to be carried in vivo via low density lipoproteins (LDL) and subsequently undergo LDL-receptor-mediated internalisation into cancer cells. In vivo anti-cancer evaluation was performed using 5-fluorouracil-cholesterol conjugate in a mouse model. The obtained prodrugs were more potent than 5-fluorouracil control drug at the same 5-fluorouracil content (3 mg·kg-1).

Matrix-molecule induced chiral enhancement effect of binary supramolecular liquid crystals

Ma, Xiao-Jing,Shen, Yong-Tao,Deng, Ke,Tang, Hong,Lei, Sheng-Bin,Wang, Chen,Yang, Yan-Lian,Feng, Xi-Zeng

, p. 4699 - 4704 (2007)

Chiral enhancement effects associated with supramolecular liquid crystalline structures are studied, using a complex of achiral molecules (4,4′-bipyridine, 4Bpy) and chiral cholesteric liquid crystalline molecules (3-cholesteryloxycarbonylpropanoic acid, C4) as the model system. Non-mesogenic achiral molecule 4Bpy is used as the matrix element. The chiral enhancement of the supramolecular liquid crystalline structures can be revealed by circular dichroism (CD) and helical twisting power measurements. It is interesting that CD spectra of the complex exhibited an appreciably enhanced chiral property in comparison with that of the pure chiral cholesteric C4 molecules at room temperature. The helical pitch measurements by the Grandjean-Cano method also confirm the chiral enhancement effect. In addition, polarizing optical microscopy (POM) measurements indicate that the addition of matrix molecules leads to the explicit expression of the chiral liquid crystalline texture, i.e. twisted grain boundary (TGBA*) phase, at the liquid crystal temperature. Differential scanning calorimetry (DSC) and variable-temperature X-ray diffraction measurements further confirm the existence of the TGBA* phase. The binary supramolecular assembly structures are investigated by scanning tunneling microscope (STM) and the formation of hydrogen bonds between the chiral mesogens and the achiral matrix molecules can be directly observed. The variable-temperature Fourier transform infrared (FTIR) results further demonstrate that the hydrogen bonds persist until 168 °C. These results indicate that the introduction of a bifunctional aromatic base such as bipyridine could lead to self-assembled supramolecular architectures with discernible enhancements of chiral properties. The Royal Society of Chemistry.

Microtubes self-assembled from a cholesterol-modified nucleoside

Pescador, Paula,Brodersen, Nicolai,Scheidt, Holger A.,Loew, Martin,Holland, Gudrun,Bannert, Norbert,Liebscher, Juergen,Herrmann, Andreas,Huster, Daniel,Arbuzova, Anna

, p. 5358 - 5360 (2010)

We describe the formation of lipid microtubes from a novel cholesterol-modified nucleoside in binary mixture with phospholipids. Stable cylindrical structures with an outer diameter of 2-3 μm and a length of 20-40 μm were formed. By varying the preparation conditions, thinner tubules with nanometre-scale diameters could also be obtained.

Synthesis of novel thiol-reactive amphiphilic lipids based on cholesterol for protein-liposome coupling

Kley, Joerg T.,Fichert, Thomas,Massing, Ulrich

, p. 319 - 327 (1998)

The synthesis of a series of coupling lipids designed for covalently linking proteins to liposomes is described. The new compounds have in common a cholesterylsuccinyl unit as a lipid anchor and a thiol-reactive maleimidobenzoyl unit which are linked by alkyl or (poly)ethylene glycol spacers that differ in length and polarity.

Synthesis of cationic cholesterol derivatives with succinyl spacer group

Konstantinova,Klykov,Maslov,Serebrennikova

, p. 1189 - 1191 (2002)

Syntheses of N, N, N-trimethyl [2-(3β-cholesteryloxy) syccinyloxyethyl] ammonium iodide, N,N-dimethyl-N-2-hydroxyethyl [2-(3β-cholesteryloxy)syccinyloxyethyl]ammonium iodide, and N-[(3β-cholesteryloxy)syccinyl]piperazine were performed. The compounds synthesized in a liposomal form may be used for delivery of genetical material into cells.

Synthesis of α-carboranyl-α-acyloxy-amides as potential BNCT agents

Jonnalagadda, Subash C.,Cruz, Jonathan S.,Connell, Ryan J.,Scott, Patricia M.,Mereddy, Venkatram R.

, p. 4314 - 4317 (2009)

Novel α-carboranyl-α-acyloxy-amides were prepared as potential BNCT agents utilizing three-component Passerini reaction. Preliminary cytotoxicity of the representative compounds on two brain tumor cell lines (U-87 and A-172) showed no effect on cell viability; an essential requirement for utility as potential BNCT agents.

In-plane modulated smectic ? vs smectic 'A' lamellar structures in poly(ethyl or propyl ether imine) dendrimers

Kumar, Prabhat,Shankar Rao,Krishna Prasad,Jayaraman

, p. 98 - 104 (2016)

A pair of first and second generation poly(alkyl ether imine) dendrimers is prepared, having covalently attached cholesteryl moieties at their peripheries. The pairs in each generation differ in the alkyl-linker which constitute the dendritic core moieties, even when the number of cholesteryl moieties remains uniform in each pair. The dendrimer pairs are two first and second generation poly(ethyl ether imine) and poly(propyl ether imine) dendrimers, modified with 4 and 8 cholesteryl esters at the peripheries in each pair, respectively. The dendrimer pairs exhibit differing thermotropic mesophase properties. Microscopic, thermal and X-ray diffraction studies reveal a lamellar mesophase for the first generation ethyl-, first and second generation propyl-linker dendrimers. Whereas, the second generation ethyl-linker dendrimer exhibits a layered structure with a superimposed in-plane modulation, the length of which corresponds to a rectangular column width. The role of the dendrimer core moieties with differing linkers in modifying the mesophase properties is studied.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1510-21-0